Neuronetics falls after dour 2023 revenue forecast
** Shares of medtech firm Neuronetics Inc STIM.O fall
16.1% to $4.37
** Co expects full-year 2023 revenue to be between $66 mln
and $72 mln, below analysts' average estimate of $73.51 mln
-Refinitiv
** STIM also reports full-year 2022 revenues of $18.2 mln,
above analysts' estimates of $16.82 mln -Refinitiv
** Co beats revenue estimates for 5 quarters in a row
-Refinitiv
** Including session's move, stock up ~55% over the past 12
months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Neuronetics
See all newsNeuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Appoints Nir Naor Chief Financial Officer Announces Additional Management Changes